Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean Louis Pujol

Showing results (31-40 of 91) with videos related to

Pageof 10
Sort By:
Bulletin Du Cancer|May 23, 2008
[Cost-effectiveness of darbepoetin alpha in an every-3-weeks schedule]Isabelle Borget, Christos Chouaid, Nadia Demarteau, et al.
Lung Cancer (Amsterdam, Netherlands)|December 7, 2002
Combination chemotherapy without cisplatin in the treatment of advanced non-small cell lung cancerJean-Louis Pujol, Xavier Quantin, Didier Choma, et al.
American Journal of Clinical Oncology|February 3, 2005
Multimodality treatment program in invasive thymic epithelial tumorWilliam Jacot, Xavier Quantin, Sarah Valette, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 3, 2010
Interactions between cytotoxic chemotherapy and antiretroviral treatment in human immunodeficiency virus-infected patients with lung cancerAlain Makinson, Jean-Louis Pujol, Vincent Le Moing, et al.
La Revue Du Praticien|July 26, 2003
[Small cell lung carcinoma]Jean-Louis Pujol, Xavier Quantin, William Jacot, et al.
JTO Clinical and Research Reports|June 19, 2023
Brief Report: A Multidisciplinary Initial Workup for Suspected Lung Cancer as Fast-Track Intervention to Histopathologic DiagnosisJean-Louis Pujol, Grégoire Mercier, Maria Vasile, et al.
Lung Cancer (Amsterdam, Netherlands)|February 13, 2003
Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancerJean-Louis Pujol, Xavier Quantin, William Jacot, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 3, 2007
Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysisJean-Louis Pujol, Sofia Paul, Nadia Chouaki, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Gefitinib (IRESSA) with vinorelbine or vinorelbine/cisplatin for chemotherapy-naive non-small cell lung cancer patientsJean-Louis Pujol, Patrick Viens, Paul Rebattu, et al.
Lung Cancer (Amsterdam, Netherlands)|August 12, 2011
Epirubicin and ifosfamide in relapsed or refractory small cell lung cancer patientsWilliam Jacot, Jean-Louis Pujol, Mohammad Chakra, et al.
Pageof 10

Showing results (31-40 of 91) with videos related to

Sort By:
Pageof 10
Bulletin Du Cancer|May 23, 2008
[Cost-effectiveness of darbepoetin alpha in an every-3-weeks schedule]Isabelle Borget, Christos Chouaid, Nadia Demarteau, et al.
Lung Cancer (Amsterdam, Netherlands)|December 7, 2002
Combination chemotherapy without cisplatin in the treatment of advanced non-small cell lung cancerJean-Louis Pujol, Xavier Quantin, Didier Choma, et al.
American Journal of Clinical Oncology|February 3, 2005
Multimodality treatment program in invasive thymic epithelial tumorWilliam Jacot, Xavier Quantin, Sarah Valette, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 3, 2010
Interactions between cytotoxic chemotherapy and antiretroviral treatment in human immunodeficiency virus-infected patients with lung cancerAlain Makinson, Jean-Louis Pujol, Vincent Le Moing, et al.
La Revue Du Praticien|July 26, 2003
[Small cell lung carcinoma]Jean-Louis Pujol, Xavier Quantin, William Jacot, et al.
JTO Clinical and Research Reports|June 19, 2023
Brief Report: A Multidisciplinary Initial Workup for Suspected Lung Cancer as Fast-Track Intervention to Histopathologic DiagnosisJean-Louis Pujol, Grégoire Mercier, Maria Vasile, et al.
Lung Cancer (Amsterdam, Netherlands)|February 13, 2003
Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancerJean-Louis Pujol, Xavier Quantin, William Jacot, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 3, 2007
Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysisJean-Louis Pujol, Sofia Paul, Nadia Chouaki, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Gefitinib (IRESSA) with vinorelbine or vinorelbine/cisplatin for chemotherapy-naive non-small cell lung cancer patientsJean-Louis Pujol, Patrick Viens, Paul Rebattu, et al.
Lung Cancer (Amsterdam, Netherlands)|August 12, 2011
Epirubicin and ifosfamide in relapsed or refractory small cell lung cancer patientsWilliam Jacot, Jean-Louis Pujol, Mohammad Chakra, et al.
Pageof 10